The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Abstract
The emergence of immune checkpoint blockade therapies over the last decade has transformed cancer treatment in a wide range of tumor types. Unprecedented and durable clinical responses in difficult-to-treat cancer histologies have been observed. However, despite these promising long-term responses, the majority of patients fail to respond to immune checkpoint blockade, demonstrating primary resistance. Additionally, many of those who initially respond to treatment eventually experience relapse secondary to acquired resistance. Both primary and acquired resistance are a result of complex and constantly evolving interactions between cancer cells and the immune system. Many mechanisms of resistance have been characterized to date, and more continue to be uncovered. By elucidating and targeting mechanisms of resistance, treatments can be tailored to improve clinical outcomes. This review will discuss the landscape of immune checkpoint blockade response data, different resistance mechanisms, and potential therapeutic strategies to overcome resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–223 of 223
Prasad, V. K., Kaestner, V., & Mailankody, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4182 · Cited by 144
Wu, X., Schulte, B. C., Zhou, Y., Haribhai, D., Mackinnon, A. C., Plaza, J. A., Williams, C. B., & Hwang, S. T. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.206 · Cited by 137
Long, G. V., Dummer, R., Ribas, A., Puzanov, I. J., Vanderwalde, A. M., Andtbacka, R. H. I., Michielin, O. A., Olszanski, A. J., Malvehy, J., Cebon, J. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9568 · Cited by 124
Complex pattern of immune evasion in MSI colorectal cancer
Özcan, M., Janikovits, J., Doeberitz, M. V. K., & Kloor, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445453 · Cited by 120
Zhang, H., Conrad, D., Butler, J. J., Zhao, C., Blay, J., & Hoskin, D. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.932 · Cited by 119
Pereira, C. A., Giménez‐Xavier, P., Pros, E., Pajares, M. J., Moro, M., Gómez, A., Navarro, A., Condom, E., Morán, S., Goméz-López, G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1946 · Cited by 115
CD73 promotes tumor growth and metastasis
Zhang, B. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18068 · Cited by 106
Chung, H. C., Schellens, J. H. M., Delord, J., Perets, R., Italiano, A., Shapira‐Frommer, R., Manzuk, L., Piha-Paul, S. A., Wang, J., Zeigenfuss, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5522 · Cited by 92
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy
Dong, Z., Wu, S.-P., Liao, R.-Q., Huang, S., & Wu, Y.-L. L. C. (2016) · Tumor Biology · doi:10.1007/s13277-016-4812-9 · Cited by 91
Chang, D.-K., Sui, J., Geng, S., Muvaffak, A., Bai, M., Fuhlbrigge, R. C., Lo, A. S., Yammanuru, A., Hubbard, L., Sheehan, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0278 · Cited by 75
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency
Zhao, F., Sucker, A., Horn, S., Heeke, C., Bielefeld, N., Schrörs, B., Bicker, A., Lindemann, M., Roesch, A., Gaudernack, G., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0008 · Cited by 74
Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy
Yentz, S. E., & Smith, D. C. (2018) · BioDrugs · doi:10.1007/s40259-018-0291-4 · Cited by 70
Saha, A., & Chatterjee, S. K. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02355.x · Cited by 68
Rationale for stimulator of interferon genes–targeted cancer immunotherapy
Vargas, T. R., Benoit-Lizon, I., & Apétoh, L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.028 · Cited by 67
Regulation of Th1/Th2 Development by Antigen-Presenting Cells in vivo
Moser, M. (2001) · Immunobiology · doi:10.1078/0171-2985-00092 · Cited by 64
Hu‐Lieskovan, S., & Ribas, A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000246 · Cited by 55
Self-citationCD73: A potential biomarker for anti-PD-1 therapy
Beavis, P. A., Slaney, C. Y., Milenkovski, N., Henderson, M. A., Loi, S., Stagg, J., Kershaw, M. H., & Darcy, P. K. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046675 · Cited by 41
Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment
Blake, S. J., Ching, A. L. H., Kenna, T., Galea, R. C., Large, J., Yagita∥, H., & Steptoe, R. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119483 · Cited by 40
Derosa, L., Routy, B., Enot, D. P., Baciarello, G., Massard, C., Loriot, Y., Fizazi, K. S., Escudier, B. J., Zitvogel, L., & Albiges, L. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.462 · Cited by 39
THE TREATMENT OF INOPERABLE SARCOMA WITH THE MIXED TOXINS OF ERYSIPELAS AND BACILLUS PRODIGIOSUS.
COLEY, W. B. (1898) · JAMA · doi:10.1001/jama.1898.92450080015001d · Cited by 37
Wargo, J. A., Gopalakrishnan, V., Spencer, C. N., Karpinets, T. V., Reuben, A., Andrews, M. C., Tetzlaff, M. T., Lazar, A. J., Hwu, P., Hwu, W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3008 · Cited by 34
Self-citationJohnson, M. L., Gonzalez, R. C., Opyrchal, M., Gabrilovich, D. I., Ordentlich, P., Brouwer, S., Sankoh, S., Schmidt, E. V., Meyers, M. L., & Agarwala, S. S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9529 · Cited by 27
P2.01-058 Mutational Features Associated with Immunoreactivity in Non-Small Cell Lung Cancer
Syn, N. L. X., Tay, D., Omar, M. F. M., Teo, J. X., Lim, J., Soo, R. A., & Soong, R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.1110 · Cited by 6
Research works printed but not linked: 8
- Burnet FM, 1971, Transplant Rev, 7, 3
- Zinzani PL, 2017, Blood, 130, 2833
- Sjöblom T, 2012, Science, 268, 268
- Pereira C, 2017, Clin Cancer Res, 23, 3203, 10.1158/1078-0432.CCR-16-1946-T · DOI
- Gao ZW, 2014, Biomed Res Int, 2014, 460654
- Son C-H, 2014, J Immunother, 37, 1, 10.1097/CJI.0000000000000007 · doi:10.1097/cji.0000000000000007
- Guo ZS, 2014, Front Oncol, 4, 74
- Shi LZ, 2018, J Immunol, 200, 122.21, 10.4049/jimmunol.200.Supp.122.21 · doi:10.4049/jimmunol.200.supp.122.21
Cited by
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
Campesato, L. F., Budhu, S., Tchaicha, J., Weng, C.-H., Gigoux, M., Cohen, I. J., Redmond, D., Mangarin, L., Pourpe, S., Liu, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17750-z · Cited by 516
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
Mamdani, H., Matosevic, S., Khalid, A. B., Durm, G., & Jalal, S. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.823618 · Cited by 359
Metadata
- Authors
- Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S.
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2019-05
- Volume
- 39
- Issue
- 39
- Pages
- 147-164
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W2946126594
- Cited by
- 653
- References
- 223
- FWCI
- 33.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.